| pubmed-article:2228313 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2228313 | lifeskim:mentions | umls-concept:C0000742 | lld:lifeskim |
| pubmed-article:2228313 | lifeskim:mentions | umls-concept:C0027651 | lld:lifeskim |
| pubmed-article:2228313 | lifeskim:mentions | umls-concept:C0007634 | lld:lifeskim |
| pubmed-article:2228313 | lifeskim:mentions | umls-concept:C0004561 | lld:lifeskim |
| pubmed-article:2228313 | lifeskim:mentions | umls-concept:C1510411 | lld:lifeskim |
| pubmed-article:2228313 | lifeskim:mentions | umls-concept:C1881379 | lld:lifeskim |
| pubmed-article:2228313 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:2228313 | pubmed:dateCreated | 1990-12-27 | lld:pubmed |
| pubmed-article:2228313 | pubmed:abstractText | E mu-myc transgenic mice were back-crossed to BALB/c mice up to back-cross generation 3. The offspring that included transgene-carrying and -negative mice in approximately equal proportions were randomly divided into 2 groups. Thirty-four mice (group I) were treated with pristane, followed by A-MuLV, and 40 (group II) were injected with A-MuLV alone. Altogether, 16 lymphoid tumors developed in group I and 17 in group II. Nine of the tumors in group I and 4 in group II appeared as ascitic tumors. The ascites contained lymphoblasts and 10 to 45% plasmacytoid cells. These tumors were designated as plasmablastic lymphomas (PLs). All tumors except one were transgene-positive and did not carry translocations. An exceptional tumor in group I carried a variant 6;15 translocation but not the transgene. It obviously corresponds to the regular Abelson + pristane-induced plasmacytoma. Among 11 tested PLs, 10 had a single retroviral insertion site, while one tumor showed 3. Among 18 untreated transgenic descendants (group III), chosen randomly during serial back-crosses, 15 (83%) developed lymphomas, with no sign of plasmacytoid differentiation. The incidence was comparable in all 3 groups, assuming 50% of the mice in groups I and II to be transgenic. The time distribution of tumor development was also similar. Spleen cells from transgene-carrying mice with no clinical sign of lymphoma were infected in vitro with A-MuLV and transplanted i.p. into BALB/c recipients. PLs developed in 26 of 31 pristane-treated recipients, but in only one of 18 untreated recipients. One of 6 PLs tested was monoclonal, whereas the remaining 5 were oligoclonal. They all expressed v-abl. These results show that some of the preneoplastic B-cells that expressed constitutively active myc transgene turned into plasmablasts after infection with A-MuLV. Full development of their neoplastic potential was facilitated by the presence of pristane-granuloma. | lld:pubmed |
| pubmed-article:2228313 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2228313 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2228313 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2228313 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2228313 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2228313 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2228313 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2228313 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2228313 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:2228313 | pubmed:issn | 0020-7136 | lld:pubmed |
| pubmed-article:2228313 | pubmed:author | pubmed-author:KleinGG | lld:pubmed |
| pubmed-article:2228313 | pubmed:author | pubmed-author:RosénAA | lld:pubmed |
| pubmed-article:2228313 | pubmed:author | pubmed-author:WeberGG | lld:pubmed |
| pubmed-article:2228313 | pubmed:author | pubmed-author:WienerFF | lld:pubmed |
| pubmed-article:2228313 | pubmed:author | pubmed-author:WangY SYS | lld:pubmed |
| pubmed-article:2228313 | pubmed:author | pubmed-author:SugiyamaHH | lld:pubmed |
| pubmed-article:2228313 | pubmed:author | pubmed-author:BabonitsMM | lld:pubmed |
| pubmed-article:2228313 | pubmed:author | pubmed-author:SilvaSS | lld:pubmed |
| pubmed-article:2228313 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2228313 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:2228313 | pubmed:volume | 46 | lld:pubmed |
| pubmed-article:2228313 | pubmed:geneSymbol | E&mgr;-myc | lld:pubmed |
| pubmed-article:2228313 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2228313 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2228313 | pubmed:pagination | 845-52 | lld:pubmed |
| pubmed-article:2228313 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:2228313 | pubmed:meshHeading | pubmed-meshheading:2228313-... | lld:pubmed |
| pubmed-article:2228313 | pubmed:meshHeading | pubmed-meshheading:2228313-... | lld:pubmed |
| pubmed-article:2228313 | pubmed:meshHeading | pubmed-meshheading:2228313-... | lld:pubmed |
| pubmed-article:2228313 | pubmed:meshHeading | pubmed-meshheading:2228313-... | lld:pubmed |
| pubmed-article:2228313 | pubmed:meshHeading | pubmed-meshheading:2228313-... | lld:pubmed |
| pubmed-article:2228313 | pubmed:meshHeading | pubmed-meshheading:2228313-... | lld:pubmed |
| pubmed-article:2228313 | pubmed:meshHeading | pubmed-meshheading:2228313-... | lld:pubmed |
| pubmed-article:2228313 | pubmed:meshHeading | pubmed-meshheading:2228313-... | lld:pubmed |
| pubmed-article:2228313 | pubmed:meshHeading | pubmed-meshheading:2228313-... | lld:pubmed |
| pubmed-article:2228313 | pubmed:meshHeading | pubmed-meshheading:2228313-... | lld:pubmed |
| pubmed-article:2228313 | pubmed:meshHeading | pubmed-meshheading:2228313-... | lld:pubmed |
| pubmed-article:2228313 | pubmed:meshHeading | pubmed-meshheading:2228313-... | lld:pubmed |
| pubmed-article:2228313 | pubmed:meshHeading | pubmed-meshheading:2228313-... | lld:pubmed |
| pubmed-article:2228313 | pubmed:meshHeading | pubmed-meshheading:2228313-... | lld:pubmed |
| pubmed-article:2228313 | pubmed:meshHeading | pubmed-meshheading:2228313-... | lld:pubmed |
| pubmed-article:2228313 | pubmed:meshHeading | pubmed-meshheading:2228313-... | lld:pubmed |
| pubmed-article:2228313 | pubmed:meshHeading | pubmed-meshheading:2228313-... | lld:pubmed |
| pubmed-article:2228313 | pubmed:meshHeading | pubmed-meshheading:2228313-... | lld:pubmed |
| pubmed-article:2228313 | pubmed:meshHeading | pubmed-meshheading:2228313-... | lld:pubmed |
| pubmed-article:2228313 | pubmed:meshHeading | pubmed-meshheading:2228313-... | lld:pubmed |
| pubmed-article:2228313 | pubmed:year | 1990 | lld:pubmed |
| pubmed-article:2228313 | pubmed:articleTitle | Abelson murine leukemia virus transforms preneoplastic Emu-myc transgene-carrying cells of the B-lymphocyte lineage into plasmablastic tumors. | lld:pubmed |
| pubmed-article:2228313 | pubmed:affiliation | Department of Tumor Biology, Karolinska Institutet, Stockholm, Sweden. | lld:pubmed |
| pubmed-article:2228313 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2228313 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:2228313 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2228313 | lld:pubmed |
